GASTROINTESTINAL STROMAL TUMOR (GIST)
Clinical trials for GASTROINTESTINAL STROMAL TUMOR (GIST) explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMOR (GIST) trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMOR (GIST), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for tough stomach cancer in early trial
Disease control Recruiting nowThis first-in-human study tests an experimental oral drug called IDRX-42 in 278 adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check safety, find the right dose, and see if the drug can shrink tu…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1 • Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill HQP1351 enters human testing for stubborn cancers
Disease control Recruiting nowThis early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for tough gut tumors: experimental drug DCC-3009 enters human trials
Disease control Recruiting nowThis study tests a new drug called DCC-3009, alone or with other cancer treatments, for people with advanced gastrointestinal stromal tumor (GIST) that has stopped responding to standard therapy. About 120 participants will receive the drug in 28-day cycles for up to 2 years. The…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for GIST patients: drug combo targets resistant tumors
Disease control Recruiting nowThis early-phase trial is testing a new combination of two drugs—ziftomenib and imatinib—in adults with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib alone. The study will first find a safe dose, then check if the combination can shrink …
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Blood test may guide cancer care without biopsy
Knowledge-focused Recruiting nowThis study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists launch major effort to unlock secrets of rare stomach cancer
Knowledge-focused Recruiting nowThis study follows 400 people aged 6 and older who have a rare stomach cancer called GIST. Researchers will collect tumor tissue during surgery and study it in the lab to learn more about the disease. Participants are monitored every 6 to 12 months for up to 10 years before surge…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Stanford scientists dig into the genetics of stomach and esophageal cancers
Knowledge-focused Recruiting nowThis study at Stanford University collects tissue and blood samples from 100 adults with or at high inherited risk for stomach, esophageal, or related cancers. Researchers aim to understand how genes and proteins contribute to cancer development. The study does not test any treat…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC